Introduction
On Monday, June 1, Antibe Therapeutics (ATBPF) announced the positive top-line data from the phase 2B dose-ranging, efficacy study of their lead drug candidate ATB-346.
The news was met with an early but short-lived enthusiasm (to daily high of C$0.89, up 16%) and then closed at C$0.58, down 25%, from the previous close of C$0.77.
My previous SA article on the top-line results as announced is here, for anyone new and interested in Antibe.
Perhaps, out of a concern that the public may have somehow misunderstood the announcement, the company held a conference